LIRYC CONTINUES TRADITION OF INNOVATION WITH FIRST COMMERCIALLY APPROVED USE OF PULSED FIELD ABLATION TECHNOLOGY TO TREAT PATIENT WITH ATRIAL FIBRILLATION

On March 23rd, 2021, Pierre Jaïs and his team performed the world’s first procedure using a CE Mark-approved PFA system on a patient with atrial fibrillation (AF).  The procedure was performed in Bordeaux, France using technology from FARAPULSE, Inc. at the Bordeaux University Hospital.

Pulsed field ablation (PFA) represents a monumental elevation of the standard of care for treating AF patients by minimizing the probability of rare but very real and well-described complications such as damage to the esophagus, nerves and pulmonary veins.  Like the introduction of the pulmonary vein isolation (PVI) technique itself, pioneered at this very institute 23 years ago, PFA is positioned to unlock a new era for AF ablation. Based on my own experience and our robust data, PFA appears to be a superior tool for the PVI approach to treating AF. Pierre Jaïs, Chief Executive Officer of the Liryc Institute, Head of the electrophysiology unit, Bordeaux University Hospital

FARAPULSE is honoured to work alongside Liryc and Prof. Jaïs who played an instrumental role in refining and confirming the potential of our cardiac PFA system. In advancing this leading platform and helping to shepherd it towards commercialization, the institute again delivers on its important mission of innovating to improve care. Allan Zingeler · President & CEO at FARAPULSE

About FARAPULSE and PFA
Today, all forms of cardiac ablation to treat arrhythmias are thermal. While both radiofrequency and cryo-ablation have evolved, they nonetheless carry an inherent risk of indiscriminate thermal damage. Tissue-selective FARAPULSE PFA has emerged to be one of the most promising energy sources for cardiac ablation, including pulmonary vein isolation to treat Atrial Fibrillation. Leading with safety, FARAPULSE PFA makes durable cardiac lesions in seconds while sparing non-target tissue. As a reminder, PEF uses high-voltage electric microshocks to creates nanoscale pores in cell membranes FARAPULSE is pioneering tissue-selective PFA therapy through development and commercialization of its dedicated generator (FARASTAR), PVI-focused catheter (FARAWAVE), large-area focal catheter (FARAFLEX), precision focal catheter (FARAPOINT) and a proprietary deflectable delivery sheath (FARADRIVE). The FARAPULSE PFA system, which includes FARAWAVE, FARASTAR and FARADRIVE, received CE mark approval in January 2021 and is commercially available across Europe.